预约演示

更新于：2025-11-23

Adsorbed diphtheria-purified pertussis-tetanus combined vaccine(Osaka University)

沉淀纯化百日咳白喉破伤风混合疫苗(Osaka University)

更新于：2025-11-23

概要

基本信息

药物类型

联合疫苗、预防性疫苗

别名

Adsorbed diphtheria-purified pertussis-tetanus combined vaccine (JP17)、Adsorbed Diphtheria-purified Pertussis-tetanus Combined Vaccine (Minimum Requirements for Biological Products)、DPT ワクチン

+ [6]

靶点-

作用方式

刺激剂

作用机制

免疫刺激剂

治疗领域

感染呼吸系统疾病其他疾病

在研适应症

白喉破伤风百日咳

非在研适应症-

原研机构

Osaka University

在研机构

Mitsubishi Tanabe Pharma Corp.

非在研机构-

权益机构-

最高研发阶段批准上市

首次获批日期

日本 (2006-06-14),

白喉破伤风百日咳

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

项与沉淀纯化百日咳白喉破伤风混合疫苗(Osaka University) 相关的临床试验

JPRN-jRCT2080222663

/ Unknown status临床2期IIT

Safety of BK1301 in healthy adults

开始日期2014-11-21

申办/合作机构

Osaka University

NCT02118961

/ Completed临床3期

Confirmatory Study to Evaluate the Immunogenicity of Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed (DTaP Vaccine, BK1301) as a Booster in Adolescents

This study is designed to assess the immunogenicity and safety of DTaP vaccine (BK1301) as a booster dose in adolescents.
The purposes of this study are as follows:
* To confirm the non-inferiority of BK1301 to Adsorbed Diphtheria-Tetanus Combined Toxoid (DT toxoid) with respect to booster responses for anti-diphtheria toxoid (anti-D) and anti-tetanus toxoid (anti-T) antibodies
* To confirm that booster responses for anti-pertussis toxoid (anti-PT) and anti-Filamentous Hemagglutinin (anti-FHA) antibodies are more than 80% of participants received BK1301

开始日期2014-04-01

申办/合作机构

Mitsubishi Tanabe Pharma Corp.

[+1]

100 项与沉淀纯化百日咳白喉破伤风混合疫苗(Osaka University) 相关的临床结果

登录后查看更多信息

100 项与沉淀纯化百日咳白喉破伤风混合疫苗(Osaka University) 相关的转化医学

登录后查看更多信息

100 项与沉淀纯化百日咳白喉破伤风混合疫苗(Osaka University) 相关的专利（医药）

登录后查看更多信息

110

项与沉淀纯化百日咳白喉破伤风混合疫苗(Osaka University) 相关的文献（医药）

2024-09-01·South Dakota medicine : the journal of the South Dakota State Medical Association

2024 Scholars' Research Symposium Abstract: Effect of COVID-19 Pandemic on Routine Pediatric Vaccination Rates in 7 Upper Midwestern States.

Article

作者: Eastman, Benjamin P

INTRODUCTION:

The COVID-19 pandemic stressed healthcare systems by increasing patient loads and creating shortages of both staffing and medical supplies. As a result, the process of administering routine pediatric vaccinations was affected. Multiple studies have reported ongoing decreases in vaccination opportunities. Completed vaccinations on the vaccination schedule for the pediatric population is a highly effective public health intervention and therefore should be maintained at high rates. Decreases in routine pediatric vaccinations could lead to the spread of multiple infectious diseases. The aim of this study is to assess the impact the COVID-19 pandemic had on routine pediatric vaccination rates in South Dakota and surrounding states.

METHODS:

ChildVaxView, a publicly available and de-identified dataset, was utilized in this research. The initial focus of this study was the vaccination rates for the state of South Dakota. To give context for vaccination rates for this state, responses of participants from South Dakota as well as those from the surrounding states of Iowa, North Dakota, Nebraska, Minnesota, Montana, and Wyoming from 2012-2022 were utilized for this project. The data was divided into 2 cohorts: "pre-pandemic vaccination" and "intra-pandemic vaccination". The rates of 5 different vaccinations from these 7 states were analyzed. The basic analysis method was an independent samples test of proportions which compared the "pre-pandemic" and "intra-pandemic" vaccination rates. P-values ≤ 0.05 were considered statistically significant.

RESULTS:

Responses compared the vaccination rates of the "pre-pandemic" period to the "intra-pandemic" period for all 7-states examined. OR values and 95% CI values are shown, where values less than 1 indicate higher "intra-pandemic" rates. In terms of 24-month PCV rates, Iowa (OR=0.76, 95%CI:0.60-0.97), Montana (OR=0.75, 95%CI:0.61-0.93), Nebraska (OR=0.77, 95%CI:0.61-0.99), and North Dakota (OR=0.77,95%CI:0.61-0.96) had higher "intra-pandemic" rates; Wyoming, South Dakota, and Minnesota showed no difference. For the 24-month polio vaccine, Montana had significantly higher "intra-pandemic" rates (OR=0.73,95%CI:0.54-0.98); the remaining states showed no difference. For the 24-month DTaP vaccine, North Dakota (OR=0.84, 95%CI:0.72-0.98), MT (OR=0.84, 95%CI:0.72-0.97), and Wyoming (OR=0.84, 95%CI:0.73-0.97) had significantly higher "intra-pandemic" vaccination rates, with no difference for the other states. The 6 surrounding states did not differ from South Dakota in polio vaccination rates "pre-pandemic" (p=0.54) nor "intra-pandemic" (p=0.36); there was additionally no difference between those states and South Dakota in the "pre-" vs "intra-pandemic" comparison (p=0.27). Similar results were seen for other vaccines.

CONCLUSIONS:

In this study, rates of a substantial proportion of pediatric vaccinations increased in the states of South Dakota, Iowa, Nebraska, North Dakota, Minnesota, Montana, and Wyoming since the onset of the COVID-19 pandemic. Several reasons for this surprising outcome were considered including amendments made to the Public Readiness and Emergency Preparedness (PREP) Act, reimbursement for clinics providing vaccinations under the Vaccination for Children (VFC) program, and increasing public awareness of the safety and efficacy of routine pediatric vaccinations.

2024-08-01·Journal of racial and ethnic health disparities

Timely Prenatal and Infant Pertussis Vaccine Uptake in an Integrated Health System

Article

作者: Becerra-Culqui, Tracy ; Tseng, Hung Fu ; Ackerson, Bradley

BACKGROUND:

Hispanic infants bear the burden of pertussis infection. We examined pertussis protection from vaccination in infants with US-born and foreign-born Hispanic mothers.

METHODS:

Retrospective cohort study of infants up to 1 year of age. Secondary data of mothers with continuous membership since the 27th week of pregnancy with infants born 1/1/2012-12/31/2017 in an integrated health care delivery organization, which broadly represent the Southern California population.

RESULTS:

Foreign-born Hispanic mothers had higher prenatal tetanus, diphtheria, acellular pertussis (Tdap) uptake compared to US-born white mothers [adjusted risk ratio (aRR): 1.04, 95% confidence interval (CI): 1.03, 1.05]. Infants with mothers on Medicaid insurance disproportionately did not enroll in the health plan by the time they were eligible for their first dose of the DTaP vaccine (68.4%). Once initiating the infant vaccine series, foreign-born Hispanic mothers more likely adhered than US-born white mothers (aRR: 1.05, CI: 1.02, 1.08).

DISCUSSION:

In an integrated health system, disparities in vaccine uptake can be minimized. Infants who are born to mothers with Medicaid insurance and are not enrolled in the health plan after birth may be under-protected from pertussis.

2024-03-01·Vaccine

Cost-effectiveness analysis of pertussis booster vaccination for adolescents in Japan

Article

作者: Hoshi, Shu-Ling ; Kondo, Masahide ; Okubo, Reiko ; Tanaka, Motoko

INTRODUCTION:

In Japan, the introduction of a fifth diphtheria-tetanus-acellular pertussis (DTaP) vaccination has been considered, and adolescents aged 11-12 years old who are currently receiving the diphtheria-tetanus (DT) vaccine are one candidate group. We analyze the cost-effectiveness of replacing the DT vaccine with the DTaP vaccine for 11-year-old adolescents and investigate the indirect effect of vaccinated adolescents on unvaccinated infant siblings. We undertake two analyses using high- and low-morbidity pertussis cases, and based on the results, present suggestions for pertussis prevention in the post-COVID-19 pandemic era.

METHOD:

We used the number of pertussis cases in 2019 as the high-morbidity case and the average number of cases in 2020-2021 as the low-morbidity case, and evaluated the incremental cost-effectiveness ratio (ICER) of the DTaP strategy to the DT strategy based on quality-adjusted life years (QALYs). The economic model contained adolescent and infant sub-models. The indirect effect for infants was considered as the probability of unvaccinated infants avoiding pertussis infection from their vaccinated siblings.

RESULTS:

The ICER from the payers' perspective was Japanese yen (JPY) 4,254,515 per QALY gained in the high-morbidity case and JPY 62,546,776 per QALY gained in the low-morbidity case. The sensitivity analysis showed that the utility of pertussis had the greatest impact on the ICER, with a 60.58% and 0% probability that the ICER was less than JPY 5 million per QALY gained in the high-morbidity case and low-morbidity case, respectively.

CONCLUSION:

The cost-effectiveness of replacing the DT vaccine with the DTaP vaccine is affected by the level of pertussis morbidity, with the ICER becoming more favorable in the high-morbidity case. The indirect effect has little impact on the ICER. Thus, policy-makers should continue to monitor the pertussis epidemic in the post-COVID-19 era, and determine the need to introduce a booster based on perceived trends.

项与沉淀纯化百日咳白喉破伤风混合疫苗(Osaka University) 相关的新闻（医药）

2025-01-06

·drugs

U.S. Whooping Cough Cases Surge

MONDAY, Jan. 6, 2025 -- Rates of whooping cough in the U.S. continue to climb, according to data from the US Centers for Disease Control (CDC). Over 32,000 cases reported have been reported as of mid-December -- about six times more than there were at this time last year, and more than there have been since 2014, according to CNN. Whooping cough, also known as pertussis, is a very contagious respiratory illness that spreads through bacteria in the air. It is common in the United States, with frequent outbreaks. Reported cases have been climbing for several months with about a quarter of all cases reported in Illinois, Indiana and other states in the Midwest. Pennsylvania has more reported cases compared to other states. Some states, such as Oregon, ticked a record high number of cases recently. For 2024, Oregon recorded the highest number of whooping cough cases since 1950, a news release stated. Typically, the infection starts with cold-like symptoms before a serious, full-body cough can develop. The name comes from the sound people make as they try to catch their breath between coughs. The coughing can last for several weeks or even months. Cases dropped during the pandemic, but according to the CDC, recent trends suggest that the U.S. is returning to pre-pandemic levels. Whooping cough can be serious for people of all ages, yet children younger than one year old are especially vulnerable because their immune systems are not fully developed. Prevention in the form of vaccination is the best way to protect against whooping cough, the CDC says; the agency recommends that children get the DTaP vaccine and adolescents and adults get the TDaP vaccine. Among children, vaccination rates for this infectious disease have fallen with only about 92% of kindergartners having gotten their DTaP vaccine for the 2023-2024 school year. Antibiotics can treat the infection, but they work best if it’s caught within the first few weeks. If you think you've been exposed to the respiratory illness, ask your doctor about preventive antibiotics. Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

疫苗

2025-01-06

·drugs

Pertussis Cases Surging in the United States

MONDAY, Jan. 6, 2025 -- Rates of pertussis in the United States are surging, with more than 32,000 cases reported as of mid-December -- about six times more than at this time last year and more than have been reported since 2014 , according to data from the U.S. Centers for Disease Control and Prevention. Reported cases have been climbing for several months, CNN reports. About a quarter of all cases have been reported in Illinois, Indiana, and other states in the Midwest. Pennsylvania has more reported cases compared with other states. Some states, such as Oregon, ticked a record high number of cases recently. For 2024, Oregon recorded the highest number of pertussis cases since 1950, Oregon Public Broadcasting reported. Cases dropped during the pandemic, but, according to the CDC, recent trends suggest that the United States is returning to prepandemic levels. Prevention, in the form of vaccination, is the best way to protect against whooping cough, the CDC says; the agency recommends that children get the DTaP vaccine and adolescents and adults get the Tdap vaccine. Among children, vaccination rates have fallen; only about 92 percent of kindergartners had gotten their DTaP vaccine for the 2023–2024 school year. This is below the 95 percent federal target. More Information Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

疫苗

100 项与沉淀纯化百日咳白喉破伤风混合疫苗(Osaka University) 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D05356	-	J07AJ52	-

研发状态

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
白喉	日本	Mitsubishi Tanabe Pharma Corp.	2006-06-14
破伤风	日本	Mitsubishi Tanabe Pharma Corp.	2006-06-14
百日咳	日本	Mitsubishi Tanabe Pharma Corp.	2006-06-14

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02118961 (CTgov)	临床3期	白喉 \| 百日咳 \| 破伤风	446	Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed (DTaP vaccine, BK1301) (BK1301)	遞鬱壓構鬱糧糧窪淵範 = 網鹹選鹽鑰顧積製壓願積壓繭鹽齋觸鹹網憲餘 (鹽繭鑰鬱顧壓餘簾憲窪, 選遞網鹽網遞壓網積顧 ~ 襯構願艱願艱衊襯餘積) 更多	-	2016-11-21
				Diphtheria-Tetanus Combined Toxoid (+DT toxoid)+Adsorbed (DT Toxoid)	遞鬱壓構鬱糧糧窪淵範 = 醖範鹹繭鹽顧壓築齋範積壓繭鹽齋觸鹹網憲餘 (鹽繭鑰鬱顧壓餘簾憲窪, 網鹹鑰鑰齋醖範夢築醖 ~ 憲簾鏇鬱範淵範獵壓淵) 更多